This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.
The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.
Discussion points:
- Key emerging trends on market access
- How agencies are approaching assessments for melanoma, lung cancer and RCC
- Specific review of PD-1 testing in health technology assessments
- Explore the move in the treatment towards combination therapies
Presenters:
- David Sykes – Founding Partner
- Clare Jones – Director
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.